Company Sartorius Stedim Biotech
Equities
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.3 EUR | +2.41% | +3.84% | -13.03% |
04-23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
04-22 | Sartorius Stedim: in the red with brokerage comments | CF |
Business Summary
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
Number of employees: 10,493
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceuticals
100.0
%
| 3,493 | 100.0 % | 2,776 | 100.0 % | -20.53% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
35.1
%
| 1,215 | 34.8 % | 973 | 35.1 % | -19.90% |
EMEA
26.7
%
| 906 | 25.9 % | 741 | 26.7 % | -18.17% |
Asia Pacific
10.4
%
| 345 | 9.9 % | 288 | 10.4 % | -16.34% |
Germany
9.1
%
| 299 | 8.6 % | 253 | 9.1 % | -15.47% |
China
6.9
%
| 377 | 10.8 % | 191 | 6.9 % | -49.38% |
South Korea
5.4
%
| 175 | 5.0 % | 149 | 5.4 % | -14.71% |
France
3.6
%
| 114 | 3.3 % | 100 | 3.6 % | -12.80% |
Americas
2.9
%
| 63 | 1.8 % | 81 | 2.9 % | +28.57% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 | |
Petra Kirchhoff
IRC | Investor Relations Contact | 55 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Lothar Kappich
BRD | Director/Board Member | 67 | 17-09-13 |
Pascale Boissel
BRD | Director/Board Member | 57 | 19-03-25 |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 | |
Director/Board Member | 62 | 15-04-06 | |
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 92,180,190 | 29,470,560 ( 31.97 %) | 15,191 ( 0.0165 %) | 31.97 % |
Company contact information
Sartorius Stedim Biotech SA
Zone Industrielle Les Paluds Avenue de Jouques
13400, Aubagne
+33 4 42 84 56 00
http://www.sartorius.comGroup companies
Name | Category and Sector |
---|---|
Sartorius Stedim Biotech GmbH
Sartorius Stedim Biotech GmbH Medical SpecialtiesHealth Technology Part of Sartorius AG, Sartorius Stedim Biotech GmbH is a company based in Goettingen, Germany. The CEOs are Helge Henning, Michaela Pischke. The German company was founded in 2007. |
Medical Specialties
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.03% | 21.64B | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- DIM Stock
- Company Sartorius Stedim Biotech